OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX EBITDA Margin
EBITDA as a percentage of revenue.
OptimizeRx CorporationNASDAQ: OPRX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 7.9%
EBITDA Margin was 7.9% in Q1 FY2026, up 12.0 pp from a year earlier. On a trailing-twelve-month basis it was 17.6%, up 23.8 pp year over year. Over 3 fiscal years it widened by 30.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 29.5% for the fiscal year ending Dec 2026, up from 15.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 7.9%-22.4 pp QoQ
- Last fiscal yearDec 2025
- 15.1%+24.8 pp YoY
- LTMMar 2026
- 17.6%+23.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.0 pp | +7.7 pp | -4.3 pp |
| 1 year | +24.8 pp | +14.4 pp | -10.4 pp |
| 3 years | +30.2 pp | +14.0 pp | -16.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 15.1%
- Year-over-year change
- +24.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.1% | +24.8pp |
| FY2024 | 2024-12-31 | -9.7% | +20.1pp |
| FY2023 | 2023-12-31 | -29.8% | -14.7pp |
| FY2022 | 2022-12-31 | -15.1% | -18.9pp |
| FY2021 | 2021-12-31 | 3.8% | — |
EBITDA Margin vs competitors
How OPRX compares with its peers on the latest reported figures
- OPRX's LTM Mar 2026 EBITDA Margin of 17.6% is the 3rd highest of the 9 companies compared; the peer median is 7.1%.
- Its year-over-year change of +23.8 pp is the 2nd highest of 9, against a peer median of -4.8 pp.
- Over three fiscal years its change of +30.2 pp compares with a peer median of -6.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Feb 2026 | 21.5% | +0.4 pp | -16.1 pp | |
| LTM Mar 2026 | 20.1% | -9.1 pp | -10.5 pp | |
| LTM Mar 2026 | 17.6% | +23.8 pp | +30.2 pp | |
| LTM Mar 2026 | 16.3% | -1.8 pp | +14.4 pp | |
| LTM Mar 2026 | 9.4% | -3.3 pp | -2.4 pp | |
| LTM Mar 2026 | 4.9% | +295.3 pp | -78.9 pp | |
| LTM Mar 2026 | -33.9% | -19.3 pp | +89.0 pp | |
| LTM Mar 2026 | -81.4% | -6.3 pp | +87.8 pp | |
| LTM Mar 2026 | -7060.9% | -6900.9 pp | -2402.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding OPRX) | 7.1% | -4.8 pp | -6.4 pp | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.29M | 62.45M | 71.52M | 92.13M | 109.43M |
| Cost of Revenue | 25.65M | 23.48M | 28.62M | 32.75M | 40.16M |
| Gross Profit | 35.64M | 38.97M | 42.9M | 59.38M | 69.27M |
| Gross Margin | 58.1% | 62.4% | 60.0% | 64.5% | 63.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 33.19M | 49.24M | 58.02M | 61.27M | 50.25M |
| Operating Expenses | 35.28M | 51.26M | 69.3M | 73.08M | 57.21M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| EBITDA | 2.34M | (9.42M) | (21.31M) | (8.9M) | 16.57M |
| EBITDA Margin | 3.8% | -15.1% | -29.8% | -9.7% | 15.1% |
| Operating Income | 361.1K | (12.29M) | (26.4M) | (13.71M) | 12.06M |
| Operating Margin | 0.6% | -19.7% | -36.9% | -14.9% | 11.0% |
| Interest Income | 16.98K | 852.3K | 2.19M | 329K | 353K |
| Interest Expense | 0 | 0 | 1.45M | 6.16M | 5.29M |
| Other Income / Expenses | 16.98K | 852.3K | 1.24M | (5.68M) | (5.11M) |
| Income Before Tax | 378.08K | (11.44M) | (25.16M) | (19.39M) | 6.95M |
| Pre-Tax Margin | 0.6% | -18.3% | -35.2% | -21.0% | 6.4% |
| Income Tax Expense | 0 | 0 | (7.6M) | 725K | 1.82M |
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Net Margin | 0.6% | -18.3% | -24.6% | -21.8% | 4.7% |
| EPS (Basic) | 0.02 | (0.64) | (1.03) | (1.10) | 0.28 |
| EPS (Diluted) | 0.02 | (0.64) | (1.03) | (1.10) | 0.27 |
| Weighted Avg Shares | 17.23M | 17.78M | 17.12M | 18.29M | 18.56M |
| Weighted Avg Shares (Diluted) | 17.69M | 17.78M | 17.12M | 18.29M | 19M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.